Immune tweak shows promise for ALS in early trial
NCT ID NCT02059759
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study tested whether low doses of interleukin-2 (IL-2) can safely boost regulatory T cells in people with amyotrophic lateral sclerosis (ALS). 36 participants received either IL-2 or a placebo for five days. The goal was to see if this immune-modulating approach could help control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de Montpellier - Hôpital Gui de Chauliac
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can a cancer drug slow ALS? a trial aims to find out
- Can conversation unlock clues to ALS speech decline?
- Could a simple Pre-Tube ritual ease feeding problems in ALS?
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- A muscle test in the thigh may reveal how ALS attacks the body